When a medication can save lives but also carry serious, even deadly, risks, how do you make sure it’s used safely? That’s the problem the FDA’s REMS programs were built to solve. REMS stands for Risk Evaluation and Mitigation Strategies. It’s not just another layer of paperwork - it’s a targeted, sometimes strict, system designed to keep patients safe while still letting them access life-saving drugs. If you’ve ever waited an extra week to get a prescription filled, or been asked to sign forms or get blood tests before starting a new medication, you’ve likely run into a REMS program.
Why REMS Programs Exist
Not every drug needs special handling. Most medications come with a standard label that lists side effects, warnings, and dosing instructions. That’s enough for about 95% of drugs. But for the other 5% - the ones tied to serious, sometimes irreversible harm - the FDA steps in. REMS was created in 2007 under the Food and Drug Administration Amendments Act (FDAAA). Before that, high-risk drugs like thalidomide, isotretinoin, and clozapine were already being tightly controlled, but there was no formal system. REMS brought all of those scattered efforts under one rulebook.These aren’t drugs you’d take for a cold or headache. They’re used for conditions like cancer, schizophrenia, epilepsy, or severe acne - diseases where the risk of not treating is just as bad as the risk of the drug itself. Thalidomide, for example, can cause severe birth defects. Isotretinoin (Accutane) carries the same risk. Clozapine can wipe out white blood cells, leaving patients vulnerable to deadly infections. Without controls, these drugs would be too dangerous to approve. With REMS, they can still be used - but only under strict conditions.
How REMS Works: The Three Key Pieces
Every REMS program is custom-built for the specific drug. But they all include at least one of these three core elements:- Medication Guides: These are printed handouts given to patients when they pick up the prescription. They explain the risks in plain language - no medical jargon. For example, a guide for Zyprexa Relprevv (an injectable antipsychotic) warns patients they could pass out or become confused right after the shot.
- Communication Plans: These are messages sent to doctors, pharmacists, and sometimes nurses. They might include training videos, emails, or updates about new safety data. The goal is to make sure providers know exactly how to use the drug safely.
- Elements to Assure Safe Use (ETASU): This is where REMS gets serious. ETASU requirements can include:
- Only certified prescribers can write the prescription
- Patient enrollment in a registry (like the iPLEDGE system for isotretinoin)
- Special pharmacies that can only dispense the drug under strict rules
- Regular lab tests - like weekly blood draws for clozapine patients
- Observation periods after administration - for example, patients taking Zyprexa Relprevv must be monitored for three hours after each injection
These aren’t suggestions. They’re requirements. Skip a step, and the pharmacy won’t fill the prescription. Skip a step, and the doctor could face legal consequences.
Who’s in Charge? The Sponsor, Not the FDA
Here’s something many people don’t realize: the FDA doesn’t run REMS programs. The drugmaker does. If you’re taking a drug with a REMS, the company that makes it is legally responsible for setting up the system, training providers, managing registries, tracking data, and reporting back to the FDA. That means if you’re a pharmacist trying to verify a patient’s eligibility, you’re logging into a portal run by AbbVie, Pfizer, or another company - not the FDA.This setup has pros and cons. On one hand, it lets companies design systems that fit their drug’s unique risks. On the other, it creates a patchwork of different websites, login systems, and procedures. A 2022 survey found that only 35% of REMS programs talk directly to electronic health records. That means pharmacists often have to copy-paste data between systems - adding 15 to 20 minutes per REMS prescription. For busy clinics, that’s hours of extra work every week.
REMS in the Real World: Delays and Frustrations
Ask any pharmacist or doctor who works with REMS drugs, and they’ll tell you: it’s slow. A 2019 study in JAMA Internal Medicine found that REMS drugs took an average of 5.4 days longer to reach patients than non-REMS drugs. For someone with cancer or a seizure disorder, that delay can be dangerous.The iPLEDGE program for isotretinoin is a classic example. To get the drug, female patients must prove they’re not pregnant (via two negative pregnancy tests), use two forms of birth control, and complete monthly counseling. All of this must be documented online. A Reddit thread from September 2023 had over 140 comments from pharmacists describing how patients wait 3 to 7 days just to get their first prescription. One pharmacist wrote: “I had a 17-year-old girl cry because she couldn’t start treatment before her school trip. The system didn’t let us move fast enough.”
Doctors feel it too. A 2022 American Medical Association survey found that 68% of physicians reported delays in starting REMS drugs. Forty-two percent said those delays hurt patient outcomes. One oncologist shared: “I had a patient with multiple myeloma. The drug worked wonders - but we couldn’t start it for 11 days because the REMS portal was down. By then, her cancer had progressed.”
Changes Are Coming - And So Are New Challenges
The FDA knows REMS isn’t perfect. In 2023, they updated their assessment template to force drugmakers to ask: “Are we creating more barriers than safety?”Some programs are being retired. Thalidomide’s REMS was officially ended in August 2023 - after 20 years - because better education and alternative treatments made the old system unnecessary. That’s a sign the FDA is learning.
They’re also testing new tools. Pilot programs are now using smartphone apps to monitor patients on blood thinners. Instead of monthly clinic visits, patients use their phone to log symptoms and upload data. If something looks off, the system alerts the doctor. Early results show promise.
But the system is still growing. In 2015, there were 34 REMS programs. By October 2023, there were 78 - covering about 150 drugs. Oncology drugs make up nearly 40% of them. That’s because newer cancer treatments are powerful but risky. A 2023 industry report predicts that by 2027, nearly half of all new cancer drugs will need REMS.
The Big Question: Is It Working?
No one argues that REMS saves lives. It’s how we got safe access to clozapine, thalidomide, and isotretinoin without mass tragedies. But the cost? It’s high. Drug companies spend an estimated $1.2 billion a year just to run these programs. The FDA issued 17 warning letters in 2022 for REMS failures. One company paid a $2.1 million fine for not properly tracking clozapine blood tests.And here’s the uncomfortable truth: we don’t always know if REMS actually prevents harm. A joint FDA-PhRMA report in September 2023 found that 63% of current REMS programs don’t have clear metrics to prove they’re working. Are the extra steps reducing deaths? Or are they just slowing people down?
Some experts say we need to rethink this. Dr. Aaron Kesselheim from Harvard testified in 2021 that opioid REMS required prescriber training but didn’t check if patients were actually being monitored - and that did little to stop misuse. Others, like former FDA deputy director Dr. Robert Temple, say REMS made it possible to approve drugs that otherwise would’ve been banned.
The truth? It’s both. REMS is necessary. But it’s also broken in places. The goal isn’t to eliminate all risk - that’s impossible. It’s to balance safety with access. And right now, too often, the scale tips too far toward bureaucracy.
What’s Next?
The FDA’s 2024-2026 plan includes modernizing REMS with digital tools: apps, automated alerts, better EHR integration. They’re also pushing for simpler, smarter programs - especially for rare diseases where patients travel hundreds of miles for care. One idea? Let patients use telehealth visits to meet REMS requirements instead of in-person trips.For now, if you’re prescribed a drug with a REMS, expect delays. Expect paperwork. Expect to be asked questions you didn’t expect. But also know this: those steps exist because someone, somewhere, almost died because they didn’t exist.
